Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Jounce Therapeutics Inc (JNCE)

Jounce Therapeutics Inc (JNCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 194,057
  • Shares Outstanding, K 33,229
  • Annual Sales, $ 65,200 K
  • Annual Income, $ -27,380 K
  • 60-Month Beta 4.05
  • Price/Sales 1.18
  • Price/Cash Flow N/A
  • Price/Book 0.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.41
  • Number of Estimates 5
  • High Estimate 0.30
  • Low Estimate -0.75
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -583.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.55 +5.23%
on 02/14/20
8.02 -27.20%
on 01/16/20
-1.60 (-21.51%)
since 01/14/20
3-Month
4.56 +28.07%
on 11/26/19
10.00 -41.60%
on 12/26/19
+0.58 (+11.03%)
since 11/14/19
52-Week
2.79 +109.32%
on 10/04/19
10.00 -41.60%
on 12/26/19
+1.54 (+35.81%)
since 02/14/19

Most Recent Stories

More News
Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker Data Supporting Use in the Upcoming SELECT Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting and Announces Research Collaboration with NanoString Technologies

- Identification of a predictive biomarker - based on an 18 gene RNA signature and vopratelimab-specific threshold (TIS) - for the emergence of ICOS hi CD4 T cells that predicted clinical benefit in patients...

JNCE : 5.84 (+1.21%)
NSTG : 33.70 (+7.60%)
Jounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E., to its Board of Directors

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of...

JNCE : 5.84 (+1.21%)
Is Jounce Therapeutics (JNCE) Stock Outpacing Its Medical Peers This Year?

Is (JNCE) Outperforming Other Medical Stocks This Year?

JNCE : 5.84 (+1.21%)
Jounce Therapeutics to Present New Data on a Potential Predictive Biomarker from the Vopratelimab ICONIC Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that new data from...

JNCE : 5.84 (+1.21%)
ImmunoGen (IMGN) Looks Good: Stock Adds 7.6% in Session

ImmunoGen (IMGN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

IMGN : 6.80 (+26.87%)
JNCE : 5.84 (+1.21%)
5 Russell 2000 Stocks That Crushed the Index This Year

Slowing trade conflicts and rate cuts by the Federal Reserve boost the domestic economy. The trend is expected to continue in the next year.

SPAR : 20.21 (-0.30%)
AEGN : 22.96 (-0.95%)
ICHR : 35.48 (-5.76%)
FBM : 18.18 (-0.93%)
JNCE : 5.84 (+1.21%)
Pacira's Late-Stage Study on Exparel Label Expansion Positive

Pacira (PCRX) releases positive top-line data from its phase III PLAY study evaluating the pharmacokinetics and safety of Exparel in two patient groups.

JNJ : 150.13 (+0.03%)
PCRX : 49.99 (+1.90%)
IRWD : 12.06 (-7.73%)
JNCE : 5.84 (+1.21%)
Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M

Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.

ACRX : 1.60 (-4.19%)
IRWD : 12.06 (-7.73%)
ASRT : 1.34 (-0.74%)
JNCE : 5.84 (+1.21%)
The Zacks Analyst Blog Highlights: Jounce Therapeutics, Forterra, Hibbett Sports, Foundation Building Materials and Orion Energy Systems

The Zacks Analyst Blog Highlights: Jounce Therapeutics, Forterra, Hibbett Sports, Foundation Building Materials and Orion Energy Systems

OESX : 5.98 (-3.08%)
FRTA : 13.54 (+0.37%)
HIBB : 23.37 (-2.34%)
FBM : 18.18 (-0.93%)
JNCE : 5.84 (+1.21%)
Is the Options Market Predicting a Spike in Jounce Therapeutics (JNCE) Stock?

Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.

JNCE : 5.84 (+1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade JNCE with:

Business Summary

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator,...

See More

Key Turning Points

2nd Resistance Point 6.07
1st Resistance Point 5.96
Last Price 5.84
1st Support Level 5.64
2nd Support Level 5.43

See More

52-Week High 10.00
Fibonacci 61.8% 7.25
Fibonacci 50% 6.39
Last Price 5.84
Fibonacci 38.2% 5.54
52-Week Low 2.79

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar